Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-24

The company (ever since the AHC, AHZ days) has always placed way too much emphasis on ridiculous statements whether they relate to their own internal valuation, or the market share they are going to take from competitors rather than sticking to delivering something concrete that secures the company's long term success.

At first It was the HSV-2 vaccine. Then it was we'll use cashflow from Infusions to expand CardioCel sales force, then it was expanding the CardioCel product line which different types of tissue products in sizes and application (when CardioCel never took any meaningful market share), then it was all about the tissue science, never mind the approved product that was superior but somehow they couldn't sell despite recruiting sales people all over north America then to turn around and need to sack them.

I really want to see this company succeed but every time I check in, it seems like more of the same.

Great technology worthless in the wrong hands if the execution isn't there.